LMP specific cytotoxic T lymphocytes (Children's Research Institute)

N/A

Report date: 2024/12/25 20:00:50

Base Information

Drug NameLMP specific cytotoxic T lymphocytes (Children's Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeiomyosarcomaLymphoma, Non-HodgkinHodgkin Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCatherine Bollard Children'S Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCatherine Bollard Children'S Research Institute
Active IndicationsN/A
Inactive IndicationsLeiomyosarcomaLymphoma, Non-HodgkinHodgkin Disease +[4] 

Other Information

ATC CodeN/A
Related LinksN/A